Newron to Re-Submit US NDA for Xadago (safinamide)

MILAN--(BUSINESS WIRE) July 26, 2016 --Newron Pharmaceuticals S.p.A. ( “Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, and...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news